[go: up one dir, main page]

AU2001278197A1 - Compositions and methods for improving cardiovascular function - Google Patents

Compositions and methods for improving cardiovascular function

Info

Publication number
AU2001278197A1
AU2001278197A1 AU2001278197A AU7819701A AU2001278197A1 AU 2001278197 A1 AU2001278197 A1 AU 2001278197A1 AU 2001278197 A AU2001278197 A AU 2001278197A AU 7819701 A AU7819701 A AU 7819701A AU 2001278197 A1 AU2001278197 A1 AU 2001278197A1
Authority
AU
Australia
Prior art keywords
compositions
methods
vitamins
cardiovascular function
improving cardiovascular
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001278197A
Inventor
Terri L. Butler
Clarence A. Johnson
John St. Cyr
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bioenergy Inc
Original Assignee
Bioenergy Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/677,639 external-priority patent/US6429198B1/en
Application filed by Bioenergy Inc filed Critical Bioenergy Inc
Publication of AU2001278197A1 publication Critical patent/AU2001278197A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Organic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Nutrition Science (AREA)
  • Mycology (AREA)
  • Emergency Medicine (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention relates to compositions for supplementing the diet of subjects suffering from cardiovascular or peripheral vascular disease or those at risk for such conditions. Ribose is given alone or in combination with one or a combination of vasodilators, nutrients and vitamins. Preferred vitamins include Vitamins C, B6, B12 and folic acid. Preferred nutrients include glutamine and glucose.
AU2001278197A 2000-07-28 2001-07-27 Compositions and methods for improving cardiovascular function Abandoned AU2001278197A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US22152600P 2000-07-28 2000-07-28
US60221526 2000-07-28
US09677639 2000-10-03
US09/677,639 US6429198B1 (en) 1999-04-12 2000-10-03 Compositions for increasing athletic performance in mammals
US30220001P 2001-06-29 2001-06-29
US60302200 2001-06-29
PCT/US2001/041448 WO2002009727A1 (en) 2000-07-28 2001-07-27 Compositions and methods for improving cardiovascular function

Publications (1)

Publication Number Publication Date
AU2001278197A1 true AU2001278197A1 (en) 2002-02-13

Family

ID=27396950

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001278197A Abandoned AU2001278197A1 (en) 2000-07-28 2001-07-27 Compositions and methods for improving cardiovascular function

Country Status (8)

Country Link
EP (1) EP1313488B1 (en)
JP (1) JP2004505056A (en)
CN (1) CN1299690C (en)
AT (1) ATE347896T1 (en)
AU (1) AU2001278197A1 (en)
DE (1) DE60125191T2 (en)
ES (1) ES2275703T3 (en)
WO (1) WO2002009727A1 (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200406199A (en) * 2002-08-30 2004-05-01 Mitsubishi Pharma Corp Preventive and/or therapeutic agent for heart failure
JP5065570B2 (en) * 2002-09-06 2012-11-07 第一三共ヘルスケア株式会社 Vascular endothelial nitric oxide synthesis promoter
JP2007106703A (en) * 2005-10-14 2007-04-26 Nutri Kk Preventive and therapeutic composition of angiopathy
GB0607402D0 (en) * 2006-04-12 2006-05-24 Barts & London Nhs Trust Therapeutic composition and use
WO2007129618A1 (en) * 2006-05-08 2007-11-15 National University Corporation Kagawa University Inhibitor of neutrophil activation/migration factor and use thereof
US8835396B2 (en) * 2006-12-15 2014-09-16 Bioenergy, Inc. Method and compositions for improving pulmonary hypertension
WO2009065142A2 (en) * 2007-11-15 2009-05-22 Biomedical Research Foundation Of Northwest Louisiana Use of nitrite salts in chronic ischemia
WO2009094593A1 (en) * 2008-01-25 2009-07-30 Foker John E Methods and compositions for inhibiting progression to chronic cardiac failure
CN102387805A (en) * 2008-04-02 2012-03-21 生物能公司 Use of ribose in first response to acute myocardial infarction
IT1391588B1 (en) * 2008-10-15 2012-01-11 Giellepi Chemicals S P A SYNERGIC COMPOSITION FOR THE RECOVERY AND REDUCTION OF LIEVE ISCHEMIC DAMAGE
GB201223365D0 (en) * 2012-12-24 2013-02-06 Provexis Natural Products Ltd Compositions
CN106999455A (en) * 2014-12-16 2017-08-01 边钟贤 Modified taurine and the pharmaceutical composition for being used to preventing or treating metabolic disease containing modified taurine
KR101666913B1 (en) * 2014-12-23 2016-10-17 변종현 A pharmaceutical composition comprising sugar and taurine for prevention or treatment of metabolic disease
CN109998101A (en) * 2019-01-28 2019-07-12 天津星宇航天生物科技有限公司 A kind of civilian nutrient formulation of aerospace for being applicable in heart and raising crowd
CN110664824B (en) * 2019-08-09 2021-01-01 北京佳博泰和健康科技有限公司 Nutrition supporting agent and preparation method and application thereof
CN114209709A (en) * 2021-12-16 2022-03-22 海门品尚医药科技有限公司 Application of D-ribose in preparation of medicine or food for improving drug cardiotoxicity

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4871718A (en) * 1987-12-29 1989-10-03 Raymond A. Roncari Composition of matter for increasing intracellular ATP levels and physical performance levels and for increasing the rate of wound repair
US4968719A (en) * 1989-04-03 1990-11-06 Sigma Tau, Industrie Farmaceutiche Riunite Spa Method for treating vascular disease
JPH02286620A (en) * 1989-04-27 1990-11-26 Riide Chem Kk Antihypertensive agent
US5292538A (en) * 1992-07-22 1994-03-08 Metagenics, Inc. Improved sustained energy and anabolic composition and method of making
US5707971A (en) * 1995-06-07 1998-01-13 Life Resuscitation Technologies, Inc. Modulation of glycolytic ATP production
US6159942A (en) * 1998-06-19 2000-12-12 Bioenergy, Inc. Compositions for increasing energy in vivo
US6218366B1 (en) * 1998-06-19 2001-04-17 Bioenergy, Inc. Method for raising the hypoxic threshold
US6420342B1 (en) * 2000-05-08 2002-07-16 N.V. Nutricia Nutritional preparation comprising ribose and medical use thereof

Also Published As

Publication number Publication date
EP1313488B1 (en) 2006-12-13
CN1454090A (en) 2003-11-05
DE60125191T2 (en) 2007-10-25
DE60125191D1 (en) 2007-01-25
EP1313488A1 (en) 2003-05-28
JP2004505056A (en) 2004-02-19
CN1299690C (en) 2007-02-14
ES2275703T3 (en) 2007-06-16
EP1313488A4 (en) 2005-11-30
WO2002009727A1 (en) 2002-02-07
ATE347896T1 (en) 2007-01-15

Similar Documents

Publication Publication Date Title
AU2001278197A1 (en) Compositions and methods for improving cardiovascular function
EP1721612A3 (en) Immunemodulating oligosaccharides
WO2003038123A3 (en) Methods to treat diabetes and related conditions based on polymorphisms in the tcf1 gene
WO2004052295A3 (en) Compositions and methods for nutrition supplementation
DK1411960T3 (en) Food product of fortified rice bran to promote cardiovascular health
AU2466500A (en) Pharmaceutical compositions for alleviating discomfort
AU3221599A (en) Compositions comprising l-arginine, ginseng and gingko biloba for enhancing blood circulation
IL186788A0 (en) Nutritional supplement for hiv patients
WO2002040702A3 (en) Methods for the treatment of cancer and other diseases and methods of developing the same
WO2001091765A3 (en) Compositions for treating eye discomfort containing herbals and/or nutritional supplements and/or minerals and/or vitamins
WO2002094189A3 (en) Compositions and methods for treating or preventing convulsions or seizures
AU2002338230A1 (en) Food item for increasing cognitive capacity
WO2003045334A3 (en) Methods and compositions for ameliorating the undesirable effects of chemotherapy
WO2002026221A3 (en) Method and composition for supplementation of nutritional deficiencies in renal patients
WO2004024167A3 (en) Use of prebiotics, preferably glucooligosaccharide, for the prevention of the onset of type ii diabetes
AU2003214059A1 (en) Preparations containing folic acid, vitamin b6, and vitamin b12, and use thereof
WO2000057721A3 (en) Edible solids for treatment of glucose metabolism disorders
WO2003059286A3 (en) Methods and compositions for oxygen transport comprising modified hemoglobin in plasma
WO2002063973A8 (en) Flavored coffee compositions and method of making
WO2000057729A3 (en) Beverages for treatment of glucose metabolism disorders
WO1999058098A3 (en) HUMAN ANTITHROMBIN IIIs AND METHODS RELATED THERETO
WO1999056697A3 (en) Pharmaceutical composition
WO2001091766A3 (en) Compositions for treating hand and wrist discomfort containing herbals and/or nutritional supplements and/or minerals and/or vitamins
AU2003209693A1 (en) Metal salts of carnitines, dietary supplements containing same and dietary kits for counteracing sexual disorders in male subjects
WO2001003325A3 (en) Use of creatine and/or creatine derivatives for treating feelings of ill-health in women